AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33292022 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPO‐572® (600 mg/d)
Number of subjects: 51
Study 33292022 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPO‐572®
Number of subjects: 51
Study 33292022 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSO‐524®
Number of subjects: 51
Study 34503857 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific surgical guides and pre-bent titanium miniplates
Number of subjects: 20
Study 34503857 — intervention group
Group type: COMPARATOR
Intervention: Conventional interocclusal wafers with intraoperatively adapted titanium miniplates
Number of subjects: 20
Study 35212055 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help intervention website
Number of subjects: 205
Study 35212055 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 205
Study 32221684 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable biliary stents
Number of subjects: 159
Study 35049070 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rituximab (S-Rtx) 375 mg/m2
Number of subjects: 0
Study 35049070 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rituximab (LD-Rtx) 100 mg weekly for 4 weeks
Number of subjects: 0
Study 33483115 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-use App group (iApp group; n = 25)
Number of subjects: 50
Study 33483115 — intervention group
Group type: COMPARATOR
Intervention: Delayed-use App group (dApp group; n = 25)
Number of subjects: 50
Study 35258579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-intensity ultrasonography (PLIUS) for 48 weeks, self-administered for 20 minutes daily.
Number of subjects: 132
Study 35258579 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasonography for 48 weeks, self-administered for 20 minutes daily.
Number of subjects: 132
Study 35258579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-intensity ultrasonography (PLIUS) for 48 weeks.
Number of subjects: 132
Study 35258579 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasonography for 48 weeks.
Number of subjects: 132
Study 35258579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-intensity ultrasonography (PLIUS) and Sham ultrasonography.
Number of subjects: 132
Study 32209068 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal mobilization (2 Hz) for 2 minutes
Number of subjects: 30
Study 32209068 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound therapy for 2 minutes
Number of subjects: 30
Study 35049249 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa (curcumin) 200 mg
Number of subjects: 76
Study 35049249 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (MA) 500 mg
Number of subjects: 76
Study 34189834 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 50
Study 34189834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 50
Study 34189834 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GLP-1 RAs
Number of subjects: 50
Study 32285710 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (250 mL Red Bull)
Number of subjects: 42
Study 32285710 — intervention group
Group type: COMPARATOR
Intervention: Water (250 mL)
Number of subjects: 42
Study 33879118 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-weekly mobile phone calls
Number of subjects: 150
Study 33879118 — intervention group
Group type: COMPARATOR
Intervention: No phone calls (control)
Number of subjects: 150
Study 32900671 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-administered Cognitive Behavioral Therapy (ICBT) for 12 weeks
Number of subjects: 36
Study 32900671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersexual Behavior Inventory (HBI-19)
Number of subjects: 36
Study 32900671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersexual Disorder: Current Assessment Scale (HD:CAS)
Number of subjects: 36
Study 32900671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Compulsivity Scale (SCS)
Number of subjects: 36
Study 32900671 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery-Åsberg Depression Rating Scale (MADRS-S)
Number of subjects: 36
Study 32900671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM)
Number of subjects: 36
Study 32900671 — intervention group
Group type: EXPERIMENTAL
Intervention: Client Satisfaction Questionnaire (CSQ-8)
Number of subjects: 36
Study 34085898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination level among participants
Number of subjects: 2377
Study 34085898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination level by sex
Number of subjects: 2377
Study 34085898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination level by age
Number of subjects: 2377
Study 34085898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination level by occupation
Number of subjects: 2377
Study 34085898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination level by region
Number of subjects: 2377
Study 34085898 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination level by knowledge scores
Number of subjects: 2377
Study 34530800 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (health literacy and CRC training + brochure and video for eligible patients)
Number of subjects: 1024
Study 34530800 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1024
Study 35022170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on the PMT-IMB model
Number of subjects: 800
Study 35022170 — intervention group
Group type: COMPARATOR
Intervention: Standardised antenatal care (ANC)
Number of subjects: 800
Study 34859631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental General Anesthesia (DGA)
Number of subjects: 2
Study 34859631 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient treatment
Number of subjects: 2
Study 32340472 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic elevation of birthweight (1-SD increase)
Number of subjects: 0
Study 36197155 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter heel raising exercise (QHR)
Number of subjects: 26
Study 36197155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 33789728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner (Exzolt®; 0.5 mg/kg body weight) administered twice, 7 days apart via drinking water.
Number of subjects: 47000
Study 33789728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner treatment
Number of subjects: 47000
Study 32641079 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion from male donors aged < 25 years
Number of subjects: 0
Study 32641079 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion from male donors aged 25-45 years
Number of subjects: 0
Study 32641079 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion from male donors aged > 45 years
Number of subjects: 0
Study 34735596 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-surgeon bilateral TKA
Number of subjects: 136
Study 34735596 — intervention group
Group type: COMPARATOR
Intervention: Single-surgeon bilateral TKA
Number of subjects: 136
Study 33259933 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical hemithoracic radiation therapy (RHR)
Number of subjects: 108
Study 33259933 — intervention group
Group type: COMPARATOR
Intervention: Palliative radiation therapy (PR)
Number of subjects: 108
Study 35499271 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos plus home laparoscopic box trainer
Number of subjects: 17
Study 35499271 — intervention group
Group type: COMPARATOR
Intervention: Videos alone
Number of subjects: 17
Study 32851572 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 6095
Study 32851572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 6095
Study 32851572 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral therapy
Number of subjects: 6095
Study 32851572 — intervention group
Group type: EXPERIMENTAL
Intervention: Other anticoagulant treatments
Number of subjects: 6095
Study 33055515 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐Scoop spectacle lens
Number of subjects: 190
Study 33055515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study 35675073 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 1102
Study 35675073 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel
Number of subjects: 1102
Study 36253778 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning vaccination
Number of subjects: 389
Study 32198301 — intervention group
Group type: COMPARATOR
Intervention: Mesenchymal stem cell (MSC) therapy
Number of subjects: 28
Study 32198301 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of administration (intravascular vs intracerebral)
Number of subjects: 28
Study 32198301 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal of the trial (efficacy vs safety)
Number of subjects: 28
Study 32198301 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for the trial by physicians
Number of subjects: 28
Study 32198301 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-related barriers and resource needs identified by physicians
Number of subjects: 28
Study 35124654 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin treatment
Number of subjects: 95
Study 35124654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 34130758 — intervention group
Group type: EXPERIMENTAL
Intervention: OUD-CDS intervention (access to clinical decision support tool)
Number of subjects: 55
Study 34130758 — intervention group
Group type: COMPARATOR
Intervention: Control (care as usual)
Number of subjects: 55
Study 32406431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (2000 IU d‐1)
Number of subjects: 800
Study 32406431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (400 IU d‐1)
Number of subjects: 800
Study 32406431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vitamin A (2000 IU d‐1) and D (400 IU d‐1)
Number of subjects: 800
Study 32406431 — intervention group
Group type: COMPARATOR
Intervention: Standard pulmonary tuberculosis therapy alone
Number of subjects: 800
Study 35944371 — intervention group
Group type: EXPERIMENTAL
Intervention: dTMS twice a day during 2 weeks
Number of subjects: 32
Study 35944371 — intervention group
Group type: EXPERIMENTAL
Intervention: dTMS twice a day during 3 weeks
Number of subjects: 32
Study 34134834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 161
Study 34134834 — intervention group
Group type: COMPARATOR
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 161
Study 32725073 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy (1500 ml of lactated Ringer's)
Number of subjects: 46
Study 32725073 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid therapy (250 ml of lactated Ringer's)
Number of subjects: 46
Study 32725073 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy
Number of subjects: 46
Study 32725073 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid therapy
Number of subjects: 46
Study 35349019 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 impact on research engagement
Number of subjects: 15
Study 35349019 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 impact on lives
Number of subjects: 15
Study 35349019 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for research engagement during COVID-19
Number of subjects: 15
Study 34496928 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 240
Study 34496928 — intervention group
Group type: EXPERIMENTAL
Intervention: Suanzaoren decoction (SZRD)
Number of subjects: 240
Study 34496928 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with Suanzaoren decoction (SZRD)
Number of subjects: 240
Study 34496928 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 240
Study 35440333 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose vaginal capsule (500 mg) used vaginally, with a second capsule administered two hours later.
Number of subjects: 100
Study 35440333 — intervention group
Group type: COMPARATOR
Intervention: Placebo used in the control group.
Number of subjects: 100
Study 32965787 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 30
Study 32965787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35436876 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education based on Pender’s health promotion model
Number of subjects: 90
Study 35436876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 33910851 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCalizerTM and intraoperative ultrasound (IOUS)
Number of subjects: 5
Study 32664995 — intervention group
Group type: EXPERIMENTAL
Intervention: glasdegib + LDAC
Number of subjects: 116
Study 32664995 — intervention group
Group type: COMPARATOR
Intervention: LDAC
Number of subjects: 116
Study 36317276 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis gloves
Number of subjects: 206
Study 36317276 — intervention group
Group type: COMPARATOR
Intervention: Loose‐fitting gloves (control)
Number of subjects: 206
Study 34214823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple exemplar extinction (CSs and two novel dog images similar to the CS+)
Number of subjects: 134
Study 34214823 — intervention group
Group type: COMPARATOR
Intervention: Standard extinction control (matched for number of CS+ and CS- presentations)
Number of subjects: 134
Study 34214823 — intervention group
Group type: COMPARATOR
Intervention: Extended extinction control (matched for total number of extinction trials)
Number of subjects: 134
Study 34214823 — intervention group
Group type: COMPARATOR
Intervention: Other stimuli extinction control (CSs and two novel stimuli unrelated to the CS+)
Number of subjects: 134
Study 34214823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple exemplar extinction
Number of subjects: 134
Study 34214823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple, Extended, and Other stimuli groups
Number of subjects: 134
Study 33071982 — intervention group
Group type: EXPERIMENTAL
Intervention: FABP4
Number of subjects: 256
Study 33071982 — intervention group
Group type: EXPERIMENTAL
Intervention: FABP5
Number of subjects: 256
Study 33071982 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 256
Study 33071982 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate
Number of subjects: 256
Study 33071982 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 256
Study 35384909 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrendipine + captopril
Number of subjects: 3756
Study 35384909 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrendipine + spironolactone hydrochlorothiazide + captopril
Number of subjects: 3756
Study 35384909 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide + spironolactone
Number of subjects: 3756
Study 34600602 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg once daily plus abiraterone acetate 1000 mg once daily and prednisone 5 mg twice daily
Number of subjects: 982
Study 34600602 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus abiraterone acetate and prednisone
Number of subjects: 982
Study 34600602 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide plus abiraterone-prednisone
Number of subjects: 982
Study 34600602 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone-prednisone
Number of subjects: 982
Study 36423214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 230
Study 36423214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 33992229 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency transcutaneous electrical nerve stimulation (TENS) at root level
Number of subjects: 140
Study 33992229 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study 32293236 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Take Charge session (TC1, n=132)
Number of subjects: 400
Study 32293236 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Take Charge sessions (TC2, n=138)
Number of subjects: 400
Study 32293236 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Charge intervention (TC1 + TC2)
Number of subjects: 400
Study 32293236 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (n=130)
Number of subjects: 400
Study 35787704 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin treatment
Number of subjects: 10142
Study 35787704 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver function tests (ALT, AST, γGT, ALP)
Number of subjects: 10142
Study 35787704 — intervention group
Group type: EXPERIMENTAL
Intervention: γGT levels
Number of subjects: 10142
Study 35787704 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT levels
Number of subjects: 10142
Study 34791068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine‐18 fluorodeoxyglucose (18F‐FDG) PET-CT scanning (FDG‐PET) before tapering (baseline) and after maximal tapering.
Number of subjects: 79
Study 32276809 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 1020
Study 32276809 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 1020
Study 34785078 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 0
Study 32601973 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg NAC twice daily (high dose group)
Number of subjects: 75
Study 32601973 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg NAC daily (low dose group)
Number of subjects: 75
Study 32601973 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel only (control group)
Number of subjects: 75
Study 32601973 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg NAC twice daily (high dose group) and 1200 mg NAC daily (low dose group)
Number of subjects: 75
Study 34779905 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-replacement side (0.019 × 0.025-inch SS)
Number of subjects: 28
Study 34779905 — intervention group
Group type: COMPARATOR
Intervention: Replacement side (new archwire each visit)
Number of subjects: 28
Study 33782334 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat surgery
Number of subjects: 37
Study 33782334 — intervention group
Group type: COMPARATOR
Intervention: Other nonsurgical management
Number of subjects: 37
Study 33782334 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 37
Study 33782334 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgeons with neuro-oncology fellowship training
Number of subjects: 37
Study 33782334 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgeons without neuro-oncology fellowship training
Number of subjects: 37
Study 33782334 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial participation
Number of subjects: 37
Study 33830898 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-fragmented adipose tissue (MFAT) injections under ultrasound guidance
Number of subjects: 10
Study 32818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching gel activated with 915 nm diode laser (1.5 W)
Number of subjects: 65
Study 32818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching gel activated with 915 nm diode laser (2.5 W)
Number of subjects: 65
Study 32818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching gel activated with 445 nm diode laser (1 W)
Number of subjects: 65
Study 32818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching gel activated with 445 nm diode laser (1.5 W)
Number of subjects: 65
Study 32818641 — intervention group
Group type: COMPARATOR
Intervention: Bleaching gel without laser activation (control group)
Number of subjects: 65
Study 35133415 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tirzepatide
Number of subjects: 475
Study 35133415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tirzepatide
Number of subjects: 475
Study 35133415 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg tirzepatide
Number of subjects: 475
Study 35133415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 32888944 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of baseline clinical and microRNA variables
Number of subjects: 0
Study 32888944 — intervention group
Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 0
Study 32991458 — intervention group
Group type: EXPERIMENTAL
Intervention: NutriAct dietary pattern with high unsaturated fat, plant proteins, and fibres
Number of subjects: 502
Study 32991458 — intervention group
Group type: COMPARATOR
Intervention: Usual care and dietary recommendations according to the German Nutrition Society (DGE)
Number of subjects: 502
Study 32991458 — intervention group
Group type: EXPERIMENTAL
Intervention: NutriAct dietary pattern
Number of subjects: 502
Study 35778473 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly coated HIV-1 SOSIP ELISAs
Number of subjects: 0
Study 35778473 — intervention group
Group type: COMPARATOR
Intervention: Antibody-immobilized ELISAs
Number of subjects: 0
Study 35778473 — intervention group
Group type: COMPARATOR
Intervention: Randomly biotinylated Env-coated ELISAs
Number of subjects: 0
Study 35778473 — intervention group
Group type: EXPERIMENTAL
Intervention: All antigen immobilization methods
Number of subjects: 0
Study 33892641 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg/month (240 mg loading dose)
Number of subjects: 462
Study 33892641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 34323688 — intervention group
Group type: EXPERIMENTAL
Intervention: Home T2PSG
Number of subjects: 128
Study 34323688 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous T1PSG and T2PSG
Number of subjects: 128
Study 34503985 — intervention group
Group type: EXPERIMENTAL
Intervention: Navafenterol 600 µg via inhalation
Number of subjects: 73